• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子 CXCL10 调节纤维相关型肝细胞癌的肿瘤微环境。

Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma.

机构信息

Department of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.

Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, 52074 Aachen, Germany.

出版信息

Int J Mol Sci. 2022 Jul 23;23(15):8112. doi: 10.3390/ijms23158112.

DOI:10.3390/ijms23158112
PMID:35897689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9329882/
Abstract

Hepatocellular carcinoma (HCC) constitutes a devastating health burden. Recently, tumor microenvironment-directed interventions have profoundly changed the landscape of HCC therapy. In the present study, the function of the chemokine CXCL10 during fibrosis-associated hepatocarcinogenesis was analyzed with specific focus on its impact in shaping the tumor microenvironment. C57BL/6J wild type (WT) and knockout mice () were treated with diethylnitrosamine (DEN) and tetrachloromethane (CCl) to induce fibrosis-associated HCCs. deficiency attenuated hepatocarcinogenesis by decreasing tumor cell proliferation as well as tumor vascularization and modulated tumor-associated extracellular matrix composition. Furthermore, the genetic inactivation of mediated an alteration of the tumor-associated immune response and modified chemokine/chemokine receptor networks. The DEN/CCl-treated mice presented with a pro-inflammatory tumor microenvironment and an accumulation of anti-tumoral immune cells in the tissue. The most striking alteration in the tumor immune microenvironment was a vast accumulation of anti-tumoral T cells in the invasive tumor margin. In summary, our results demonstrate that CXCL10 exerts a non-redundant impact on several hallmarks of the tumor microenvironment and especially modulates the infiltration of anti-tumorigenic immune cells in HCC. In the era of microenvironment-targeted HCC therapies, interfering with CXCL10 defines a novel asset for further improvement of therapeutic strategies.

摘要

肝细胞癌(HCC)是一种严重的健康负担。最近,肿瘤微环境导向的干预措施深刻改变了 HCC 治疗的格局。在本研究中,分析了趋化因子 CXCL10 在纤维化相关肝癌发生中的作用,特别关注其对肿瘤微环境形成的影响。使用二乙基亚硝胺(DEN)和四氯化碳(CCl)对 C57BL/6J 野生型(WT)和 敲除()小鼠进行处理,以诱导纤维化相关 HCC。 缺陷通过减少肿瘤细胞增殖以及肿瘤血管生成和调节肿瘤相关细胞外基质组成来减弱肝癌发生。此外, 基因失活介导了肿瘤相关免疫反应的改变,并修饰了趋化因子/趋化因子受体网络。DEN/CCl 处理的 小鼠表现出促炎肿瘤微环境和组织中抗肿瘤免疫细胞的积累。 在 肿瘤免疫微环境中最显著的改变是抗肿瘤 T 细胞在侵袭性肿瘤边缘的大量积累。总之,我们的结果表明,CXCL10 对肿瘤微环境的几个特征具有非冗余的影响,特别是调节 HCC 中抗肿瘤免疫细胞的浸润。在肿瘤微环境靶向 HCC 治疗的时代,干扰 CXCL10 为进一步改善治疗策略提供了新的资产。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/c2bfa70488d4/ijms-23-08112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/941a1376af29/ijms-23-08112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/0dcc0c00dbd7/ijms-23-08112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/34f30ffcee75/ijms-23-08112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/d629c784a044/ijms-23-08112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/2c443b6a991b/ijms-23-08112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/23c59d99ac36/ijms-23-08112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/a574cc251889/ijms-23-08112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/c2bfa70488d4/ijms-23-08112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/941a1376af29/ijms-23-08112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/0dcc0c00dbd7/ijms-23-08112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/34f30ffcee75/ijms-23-08112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/d629c784a044/ijms-23-08112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/2c443b6a991b/ijms-23-08112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/23c59d99ac36/ijms-23-08112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/a574cc251889/ijms-23-08112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d4a/9329882/c2bfa70488d4/ijms-23-08112-g008.jpg

相似文献

1
Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma.趋化因子 CXCL10 调节纤维相关型肝细胞癌的肿瘤微环境。
Int J Mol Sci. 2022 Jul 23;23(15):8112. doi: 10.3390/ijms23158112.
2
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).干扰素调节因子 1(IRF-1)通过 CXCL10/CXCR3 轴在肝细胞癌(HCC)中激活抗肿瘤免疫。
Cancer Lett. 2021 May 28;506:95-106. doi: 10.1016/j.canlet.2021.03.002. Epub 2021 Mar 6.
3
Hepatocyte-specific Smad4 deficiency inhibits hepatocarcinogenesis by promoting CXCL10/CXCR3-dependent CD8- T cell-mediated anti-tumor immunity.肝实质细胞特异性 Smad4 缺失通过促进 CXCL10/CXCR3 依赖的 CD8+T 细胞介导的抗肿瘤免疫抑制肝癌发生。
Theranostics. 2024 Sep 9;14(15):5853-5868. doi: 10.7150/thno.97276. eCollection 2024.
4
Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.肝癌中浆细胞向 IgG 表型的极化涉及表观遗传改变,并促进小鼠肝癌进展。
Gastroenterology. 2019 May;156(6):1890-1904.e16. doi: 10.1053/j.gastro.2019.01.250. Epub 2019 Jan 31.
5
CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4 T-Cell-Dependent Control of Senescence.CXCR6 通过促进自然杀伤 T 细胞和 CD4 T 细胞依赖的衰老控制来抑制肝癌发生。
Gastroenterology. 2019 May;156(6):1877-1889.e4. doi: 10.1053/j.gastro.2019.01.247. Epub 2019 Jan 30.
6
The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.CCR2 巨噬细胞亚群促进纤维化肝脏中的肿瘤血管生成。
Cell Mol Gastroenterol Hepatol. 2019;7(2):371-390. doi: 10.1016/j.jcmgh.2018.10.007. Epub 2018 Oct 18.
7
Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma.通过抗体阵列鉴定肿瘤微环境中的趋化因子 CXCL10 作为肝细胞癌的预后标志物。
Neoplasma. 2017;64(5):778-786. doi: 10.4149/neo_2017_517.
8
The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.趋化因子受体 CCR10 通过激活 PI3K/Akt 通路促进炎症驱动的肝癌发生。
Cell Death Dis. 2018 Feb 14;9(2):232. doi: 10.1038/s41419-018-0267-9.
9
CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.CXCL2/10/12/14 是肝癌的预后生物标志物,与免疫浸润相关。
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204312.
10
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.适应性免疫抑制二乙基亚硝胺诱导的肝癌的形成和进展。
Gut. 2012 Dec;61(12):1733-43. doi: 10.1136/gutjnl-2011-301116. Epub 2012 Jan 20.

引用本文的文献

1
Dual role of CXCL10 in cancer progression: implications for immunotherapy and targeted treatment‎.CXCL10在癌症进展中的双重作用:对免疫治疗和靶向治疗的启示
Cancer Biol Ther. 2025 Dec;26(1):2538962. doi: 10.1080/15384047.2025.2538962. Epub 2025 Aug 4.
2
Progression to fibrosis and hepatocellular carcinoma in DEN CCl liver mice, is associated with macrophage and striking regulatory T cells infiltration.在二乙基亚硝胺(DEN)-四氯化碳(CCl)诱导的肝纤维化小鼠模型中,向纤维化和肝细胞癌的进展与巨噬细胞及显著的调节性T细胞浸润有关。
Front Immunol. 2025 Jul 8;16:1601215. doi: 10.3389/fimmu.2025.1601215. eCollection 2025.
3
Semaphorin 3E-Plexin-D1 Pathway Downstream of the Luteinizing Hormone Surge Regulates Ovulation, Granulosa Cell Luteinization, and Ovarian Angiogenesis in Mice.

本文引用的文献

1
Recent advances in systemic therapy for hepatocellular carcinoma.肝细胞癌全身治疗的最新进展
Biomark Res. 2022 Jan 9;10(1):3. doi: 10.1186/s40364-021-00350-4.
2
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.癌症免疫治疗中趋化因子导向的肿瘤微环境调节
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.
3
Hepatocellular carcinoma.肝细胞癌。
促黄体生成素高峰下游的信号素3E-丛状蛋白-D1通路调节小鼠排卵、颗粒细胞黄体化和卵巢血管生成。
Adv Sci (Weinh). 2025 Aug;12(29):e17163. doi: 10.1002/advs.202417163. Epub 2025 May 20.
4
Serum interferon-gamma-induced protein 10 levels can help predict sarcopenia development in patients with primary hepatocellular carcinoma: A retrospective cohort study.血清干扰素-γ诱导蛋白10水平有助于预测原发性肝细胞癌患者肌肉减少症的发生:一项回顾性队列研究。
PLoS One. 2025 May 15;20(5):e0309852. doi: 10.1371/journal.pone.0309852. eCollection 2025.
5
Targeting the atypical chemokine receptor 2 () improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.靶向非典型趋化因子受体2()可提高抗PD-1免疫疗法在黑色素瘤小鼠模型中的疗效。
Oncoimmunology. 2025 Dec;14(1):2494426. doi: 10.1080/2162402X.2025.2494426. Epub 2025 Apr 18.
6
Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study.探索胶质母细胞瘤治疗的潜在药物靶点:一项孟德尔随机化研究。
BMC Cancer. 2025 Apr 10;25(1):654. doi: 10.1186/s12885-025-13979-3.
7
TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway.TREML2通过抑制NF-κB/CXCL10信号通路增强急性髓系白血病细胞对化疗的敏感性。
Blood Sci. 2025 Mar 18;7(2):e00223. doi: 10.1097/BS9.0000000000000223. eCollection 2025 Jun.
8
Targeting autophagy to enhance chemotherapy and immunotherapy in oral cancer.靶向自噬以增强口腔癌的化疗和免疫治疗
Front Immunol. 2025 Jan 7;15:1535649. doi: 10.3389/fimmu.2024.1535649. eCollection 2024.
9
Radiomics Signatures Based on Computed Tomography for Noninvasive Prediction of CXCL10 Expression and Prognosis in Ovarian Cancer.基于 CT 的影像组学特征无创预测卵巢癌 CXCL10 表达及预后
Cancer Rep (Hoboken). 2024 Oct;7(10):e70030. doi: 10.1002/cnr2.70030.
10
Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.对CXCL10和MIP-3a的综合分析揭示了它们在肝细胞癌中的潜在临床应用。
Transl Oncol. 2024 Oct;48:102071. doi: 10.1016/j.tranon.2024.102071. Epub 2024 Aug 3.
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
4
Hepatic Stellate Cells and Hepatocarcinogenesis.肝星状细胞与肝癌发生
Front Cell Dev Biol. 2020 Aug 5;8:709. doi: 10.3389/fcell.2020.00709. eCollection 2020.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.CXCL10 和 CCL21 促进胰腺癌细胞向感觉神经元迁移和肿瘤内的神经重塑,与患者疼痛相关。
Gastroenterology. 2020 Aug;159(2):665-681.e13. doi: 10.1053/j.gastro.2020.04.037. Epub 2020 Apr 21.
7
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.从基础到临床:肝癌的肿瘤免疫微环境和当前免疫治疗策略。
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi: 10.1186/s13046-019-1396-4.
8
The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.CXCR3 变异体及其配体在肿瘤微环境中的独特作用。
Cells. 2019 Jun 18;8(6):613. doi: 10.3390/cells8060613.
9
The Intersection between Tumor Angiogenesis and Immune Suppression.肿瘤血管生成与免疫抑制的交集。
Clin Cancer Res. 2019 Sep 15;25(18):5449-5457. doi: 10.1158/1078-0432.CCR-18-1543. Epub 2019 Apr 3.
10
Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands.可能促成干扰素诱导的CXC趋化因子受体3配体非冗余活性的机制概述
Front Immunol. 2018 Jan 15;8:1970. doi: 10.3389/fimmu.2017.01970. eCollection 2017.